Roche's announcement of a new Phase 3 randomized, double-blind, placebo-controlled trial of Elevidys (delandistrogene moxeparvovec) for European approval goes far beyond a simple regulatory retry. While the STAT News report accurately notes the 72-week study in roughly 100 boys with early-stage Duchenne muscular dystrophy (DMD) and its intent to address the EMA's 2025 negative opinion on insufficient long-term benefit, it misses the larger pattern: this move exemplifies a fragmented global approval system that incentivizes repeated, costly trials for ultra-expensive one-time gene therapies without guaranteeing robust evidence of durable clinical value.

The original coverage underplays how this reflects systemic issues. The initial EMBARK trial (Lancet Neurology 2024; RCT, n=125 ambulatory boys aged 4-7, sponsored by Sarepta with clear conflicts of interest) missed its primary endpoint of change in NSAA score at 52 weeks versus placebo, yet secured FDA accelerated approval in 2023 based on surrogate micro-dystrophin expression. A subsequent NEJM publication (2023) on an earlier Phase 1/2 study (open-label, n=4, no control arm) reported functional stabilization signals but warned of immune responses potentially limiting durability. An observational follow-up cohort study in JAMA Neurology (2025, n=58, manufacturer-funded, no randomization) suggested slowed progression at 2 years but was underpowered for rare-event safety signals and lacked independent controls.

What STAT omitted is the economic and ethical dimension. Priced near $3.2 million per one-time infusion in the US, Elevidys joins Zolgensma ($2.1M for SMA) in straining payer thresholds. European HTA bodies like NICE and HAS demand stronger cost-effectiveness modeling than FDA surrogate-based pathways allow. This regulatory arbitrage forces companies like Roche (ex-US rights holder) and Sarepta to run parallel development programs, duplicating patient recruitment in a rare disease affecting ~1 in 5,000 male births and delaying equitable global access.

Synthesizing these sources reveals a recurring pattern across AAV-based neuromuscular therapies. Pfizer's fordadistrogene movaparvovec and Solid Biosciences' SGT-001 have faced similar mixed RCT outcomes (missed primaries, positive secondaries on velocity and biomarkers), yet the race to expand labels continues. Peer-reviewed meta-analyses (Molecular Therapy 2025; systematic review of 12 AAV-DMD trials, total n<400 across studies) highlight that while micro-dystrophin is produced, expression often wanes after 18-24 months due to immune clearance and episomal dilution in growing muscle. Long-term registries remain underdeveloped, with no harmonized international standards for what constitutes 'meaningful' benefit on functional scales like NSAA or 6MWT.

The original reporting also glossed over patient and health-system impacts. Families face devastating decisions weighing uncertain benefit against risks including myocarditis and complement activation. Health equity gaps widen: wealthier nations may adopt via special access schemes while low-resource settings are locked out. This new Roche trial, though methodologically sound as a larger RCT, still only spans 72 weeks—insufficient for a chronic, progressive condition where boys lose ambulation by their early teens.

Genuine analysis shows the field risks repeating CAR-T and enzyme-replacement pitfalls: initial hype, massive pricing, then post-market revelations of variable durability requiring redosing strategies or adjunct therapies. True progress demands aligned FDA-EMA-conditional approval frameworks, mandatory 5-10 year independent registries, and value-based payment models tied to real-world outcomes. Until then, advancing another Elevidys trial is less breakthrough than symptom of a broken incentive structure in rare-disease gene therapy development.